TopBanner

Cart empty

User Account

 

Contrived Tears with Lipids

The most advanced tear formulation available in the world today.

Our Contrived Tears with Lipids have been developed from over 60 components known to be present in tears and is our most advanced tear formulation. Our Contrived Tears with Lipids utilizes our standard contrived tears at its base, balancing Proteins, salt, pH etc, but additionally contains over 40 other hydrophilic and hydrophobic components which make up the lipid tear film, including: Free Fatty Acids; Wax Esters; Cholesterol; Cholesterol Esters; Diesters; Mucin; Free Sterols; Triglycerides; Glycerophospholipids; Sphingophosholipids; Fatty Acids and Hydrocarbons, to name but just a few of the many additional components.

Our Contrived Tears with Lipids is the only tear formulation available today which closely mimics physiological tears and is ideal for your research and diagnostic needs. These tears are available in 4.5, 9, 18 and 100 ml volumes. The Tear Osmolarity of our Contrived Tears with Lipids is in the range 300-305 mOsms/L with a pH of 7.4 and tear surface tension of between 44-49 dynes/cm, consistent with literature values.

We also offer a sterile version of our Contrived Lipid Tears in 9, 18 and 100 ml volumes.

All Ursa BioScience™ tear products are not intended for human use.

References:

[1] Vicario-de-la-Torre, M.; Benitez-del-Castillo, J. M.; Vico, E.; Guzman, M.; de-las-Heras, B.; Herrero-Vanrell, R.; Molina-Martinez, I. T., Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. Invest. Ophthalmol. Vis. Sci. 2014, 55 (12), 7839-7847.

[2] Zhang, Y. Q.; Potvin, R.; Gong, L., A Study of the Short-Term Effect of Artificial Tears on Contrast Sensitivity in Patients With Sjogren's Syndrome. Invest. Ophthalmol. Vis. Sci. 2013, 54 (13), 7977-7982.

[3] Comez, A. T.; Tufan, H. A.; Kocabiyik, O.; Gencer, B., Effects of Lubricating Agents with Different Osmolalities on Tear Osmolarity and Other Tear Function Tests in Patients with Dry Eye. Curr. Eye Res. 2013, 38 (11), 1095-1103.

[4] Gensheimer, W. G.; Kleinman, D. M.; Gonzalez, M. O.; Sobti, D.; Cooper, E. R.; Smits, G.; Loxley, A.; Mitchnick, M.; Aquavella, J. V., Novel Formulation of Glycerin 1% Artificial Tears Extends Tear Film Break-Up Time Compared with Systane Lubricant Eye Drops. J. Ocul. Pharmacol. Ther. 2012, 28 (5), 473-478.

[5] Wright, E. A.; Payne, K. A. P.; Jowitt, T. A.; Howard, M.; Morgan, P. B.; Maldonado-Codina, C.; Dobson, C. B., Preservation of Human Tear Protein Structure and Function by a Novel Contact Lens Multipurpose Solution Containing Protein-Stabilizing Agents. Eye Contact Lens-Sci. Clin. Pra. 2012, 38 (1), 36-42.

[6] Butovich, I. A., Fatty acid composition of cholesteryl esters of human meibomian gland secretions. Steroids 2010, 75 (10), 726-733.

[7] Saville, J. T.; Zhao, Z. J.; Willcox, M. D. P.; Blanksby, S. J.; Mitchell, T. W., Detection and Quantification of Tear Phospholipids and Cholesterol in Contact Lens Deposits: The Effect of Contact Lens Material and Lens Care Solution. Invest. Ophthalmol. Vis. Sci. 2010, 51 (6), 2843-2851.

[8] Knop, E.; Knop, N., Meibomian glands. Ophthalmologe 2009, 106 (11), 980-987.

[9] Wojtowicz, J. C.; Butovich, I. A.; McCulley, J. P., Historical Brief on Composition of Human Meibum Lipids. Ocul. Surf. 2009, 7 (3), 145-153.

[10] Butovich, I. A., On the lipid composition of human meibum and tears: Comparative analysis of nonpolar lipids. Invest. Ophthalmol. Vis. Sci. 2008, 49 (9), 3779-3789.

[11] Filik, J.; Stone, N., Analysis of human tear fluid by Raman spectroscopy. Anal. Chim. Acta 2008, 616 (2), 177-184.

[12] Joffre, C.; Souchier, M.; Gregoire, S.; Viau, S.; Bretillon, L.; Acar, N.; Bron, A. M.; Creuzot-Garcher, C., Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br. J. Ophthalmol. 2008, 92 (1), 116-119.

[13] Klenkler, B.; Sheardown, H.; Jones, L., Growth factors in the tear film: Role in tissue maintenance, wound healing, and ocular pathology. Ocul. Surf. 2007, 5 (3), 228-239.

[14] Ohashi, Y.; Dogru, M.; Tsubota, K., Laboratory findings in tear fluid analysis. Clin. Chim. Acta 2006, 369 (1), 17-28.

[15] Zhou, L.; Beuerman, R. W.; Foo, Y.; Liu, S.; Ang, L. P. K.; Tan, D. T. H., Characterisation of human tear proteins using high-resolution mass spectrometry. Ann. Acad. Med. Singap. 2006, 35 (6), 400-407.

[16] de Souza, G. A.; Godoy, L. M. F.; Mann, M., Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol. 2006, 7 (8).

[17] Miano, F.; Calcara, M.; Millar, T. J.; Enea, V., Insertion of tear proteins into a meibomian lipids film. Colloids and Surfaces B-Biointerfaces 2005, 44 (1), 49-55.

[18] Johnson, M. E.; Murphy, P. J., Changes in the tear film and ocular surface from dry eye syndrome. Prog. Retin. Eye Res. 2004, 23 (4), 449-474.

[19] Bron, A. J.; Tiffany, J. M.; Gouveia, S. M.; Yokoi, N.; Voon, L. W., Functional aspects of the tear film lipid layer. Exp. Eye Res. 2004, 78 (3), 347-360.

[20] Tiffany, J. M., Tears in health and disease. Eye 2003, 17 (8), 923-926.

[21] Shine, W. E.; McCulley, J. R., Polar lipids in human meibomian gland secretions. Curr. Eye Res. 2003, 26 (2), 89-94.

 

 

 

 Lipid contrived tears

 

Tears with Lipids

Tear Analytica Services w220 v2

lactoferrinV2